Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Manuel Atienza

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Nursing Education Perspectives|November 6, 2013
An advanced practice nursing program for foreign medical doctors: a practical approachPatricia T Alpert, Carolyn B Yucha, Manuel Atienza
European Spine Journal : Official Publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society|October 11, 2015
Finite element analysis and cadaveric cinematic analysis of fixation options for anteriorly implanted trabecular metal interbody cagesPedro Berjano, Juan Francisco Blanco, Diego Rendon, et al.
Future Oncology (London, England)|August 13, 2020
Abemaciclib, a CDK4 and CDK6 inhibitor for the treatment of metastatic breast cancerMiguel Martin, Jose A Garcia-Saenz, Luis Manso, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|April 7, 2023
Observational study of HR+/HER2- metastatic breast cancer patients treated with abemaciclib in Spain in the Named Patient Use Program (AbemusS)Salvador Blanch, Juan Miguel Gil-Gil, Miriam Arumí, et al.
Future Oncology (London, England)|August 8, 2024
Abemaciclib for treating patients with HR+/HER2- metastatic breast cancer: a real-world study in France, Italy and SpainIsabel Blancas, Jessica Grosjean, Rebecca Pedersini, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|March 12, 2026
Clinical experience and satisfaction in patients with advanced breast cancer participating in the abemaciclib patient support program in Spain: a prospective observational studyIsabel Blancas, Miriam González de la Peña, María Fernández Abad, et al.
European Journal of Nuclear Medicine and Molecular Imaging|April 8, 2024
Clinicopathological and molecular predictors of [<sup>18</sup>F]FDG-PET disease detection in HER2-positive early breast cancer: RESPONSE, a substudy of the randomized PHERGain trialAntonio Llombart-Cussac, Aleix Prat, José Manuel Pérez-García, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|April 4, 2024
Optimal [<sup>18</sup>F]FDG PET/CT Cutoff for Pathologic Complete Response in HER2-Positive Early Breast Cancer Patients Treated with Neoadjuvant Trastuzumab and Pertuzumab in the PHERGain TrialGeraldine Gebhart, Marleen Keyaerts, Thomas Guiot, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Nursing Education Perspectives|November 6, 2013
An advanced practice nursing program for foreign medical doctors: a practical approachPatricia T Alpert, Carolyn B Yucha, Manuel Atienza
European Spine Journal : Official Publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society|October 11, 2015
Finite element analysis and cadaveric cinematic analysis of fixation options for anteriorly implanted trabecular metal interbody cagesPedro Berjano, Juan Francisco Blanco, Diego Rendon, et al.
Future Oncology (London, England)|August 13, 2020
Abemaciclib, a CDK4 and CDK6 inhibitor for the treatment of metastatic breast cancerMiguel Martin, Jose A Garcia-Saenz, Luis Manso, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|April 7, 2023
Observational study of HR+/HER2- metastatic breast cancer patients treated with abemaciclib in Spain in the Named Patient Use Program (AbemusS)Salvador Blanch, Juan Miguel Gil-Gil, Miriam Arumí, et al.
Future Oncology (London, England)|August 8, 2024
Abemaciclib for treating patients with HR+/HER2- metastatic breast cancer: a real-world study in France, Italy and SpainIsabel Blancas, Jessica Grosjean, Rebecca Pedersini, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|March 12, 2026
Clinical experience and satisfaction in patients with advanced breast cancer participating in the abemaciclib patient support program in Spain: a prospective observational studyIsabel Blancas, Miriam González de la Peña, María Fernández Abad, et al.
European Journal of Nuclear Medicine and Molecular Imaging|April 8, 2024
Clinicopathological and molecular predictors of [<sup>18</sup>F]FDG-PET disease detection in HER2-positive early breast cancer: RESPONSE, a substudy of the randomized PHERGain trialAntonio Llombart-Cussac, Aleix Prat, José Manuel Pérez-García, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|April 4, 2024
Optimal [<sup>18</sup>F]FDG PET/CT Cutoff for Pathologic Complete Response in HER2-Positive Early Breast Cancer Patients Treated with Neoadjuvant Trastuzumab and Pertuzumab in the PHERGain TrialGeraldine Gebhart, Marleen Keyaerts, Thomas Guiot, et al.
Pageof 1